Overview

Investigation to Identify Predictors of Response to a Treatment With Montelukast

Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
The main aim of the study is to develop a method that allows responders to be distinguished from non-responders before long-term treatment is initiated. Subsidiary aims are to record changes in pulmonary functional parameters, NO concentrations and peak flow variability, the use of beta2 sympathomimetics and the asthma symptom score.
Phase:
Phase 4
Details
Lead Sponsor:
Marien Hospital Wesel
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Montelukast